x.com· @ · X·· 2026-04-22Score60
Reading
KRAS / RAS targeting: from platform to Phase 3
The floor also showed dual ON/OFF (VS-7375) and RM-055, built for amplification and daraxonrasib-resistant models.
Body
RevMed didn’t disappoint once again #AACR26. CSO Jacqueline Smith introducing a new generation of resistance-breaking tricomplex inhibitors. Moving from steric blocking of Ras-Raf interactions to induced catalytic GTP hydrolysis with RM-055. Spectacular cellular & in vivo data. https://t.co/VpPSxeAJVD
Heat 123 · 102 likes · 1 reply · 20 reposts
Source: x.com · x.com